CISCA Combination Chemotherapy in Advanced Bladder Cancer.
- Author:
Youn Kyoo CHUNG
1
;
Kwang Sae KIM
;
Sung Choon LEE
Author Information
1. Department of Urology, Keimyung University School of Medicine, Taegu, Korea.
- Publication Type:Original Article
- Keywords:
CISCA;
bladder tumor
- MeSH:
Cyclophosphamide;
Drug Therapy;
Drug Therapy, Combination*;
Humans;
Urinary Bladder Neoplasms*;
Urinary Bladder*;
Urinary Tract
- From:Korean Journal of Urology
1986;27(2):229-234
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The management of the patient with recurrent local of disseminated bladder cancer presents a difficult problem. In the majority of these patients an operation or radiation therapy is of no value. Because none of the single agent chemotherapy seems to be capable of achieving an objective response rate greater than 50 percent and because complete responses are rare, combination chemotherapy trials have been developed. In l977 Sternberg et al reports 83 percent response rate (CR: 8%, PR: 75%) with CISCA combination chemotherapy (cis-platinum, cyclophosphamide, adriamycin) in advanced urinary tract carcinoma. Other similar studies have shown various results ranging from 43 to 82 percent response rate in advanced bladder cancer. Herein, we report 3 cases of CISCA combination chemotherapy in far advanced bladder cancer, which had measurable metastatic lesions enough to evaluate the objective response of chemotherapy.
